Overview Financials News + Filings IR Vault Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Appointed director
|
|
Merck & Co., Inc. (MRK)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/01/2023 |
8-K
| Quarterly results |
| 05/26/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/17/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"4.050% Notes due 2028 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2028 Notes",
"4.300% Notes due 2030 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2030 Notes",
"4.500% Notes due 2033 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2033 Notes",
"4.900% Notes due 2044 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2044 Notes",
"5.000% Notes due 2053 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2053 Notes",
"5.150% Notes due 2063 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2063 Notes",
"Opinion and Consent of Jennifer Zachary, Esq., Executive Vice President and General Counsel of the Company" |
|
| 04/27/2023 |
8-K
| Quarterly results |
| 02/02/2023 |
8-K
| Quarterly results|
Docs:
|
"Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results",
"MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP Table 1a 2022 2021 % Change 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year 4Q Full Year Sales $ 15,901 $ 14,593 $ 14,959 $ 13,830 $ 59,283 $ 10,627 $ 11,402 $ 13,154 $ 13,521 $ 48,704 2 % 22 % Costs, Expenses and Other Cost of sales 5,380 4,216 3,934 3,881 17,411 3,199 3,104 3,450 3,873 13,626 0 % 28 % Selling, general and administrative 2,323 2,512 2,520 2,687 10,042 2,187 2,281 2,336 2,830 9,634 -5 % 4 % Research and development 2,576 2,798 4,399 3,775 13,548 2,412 4,321 2,445 3,068 12,245 23 % 11 % Restructuring costs 53 142 94 49 337 297 82 107 174 661 -72 % -49 % Other expense, net 708 438 429 1,501 -77 % * Income from Continuing Operations Before Taxes 4,861 4,487 3,583 3,513 16,444 2,987 1,717 5,266 3,909 13,879 -10 % 18 % In..." |
|
| 10/27/2022 |
8-K
| Quarterly results |
| 07/28/2022 |
8-K
| Quarterly results |
| 05/26/2022 |
8-K
| Quarterly results |
| 04/28/2022 |
8-K
| Quarterly results|
Docs:
|
"Merck Announces First-Quarter 2022 Financial Results",
"MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP Table 1a 2022 2021 % Change 1Q 1Q 2Q 3Q 4Q Full Year 1Q Sales $ 15,901 $ 10,627 $ 11,402 $ 13,154 $ 13,521 $ 48,704 50 % Costs, Expenses and Other Cost of sales 5,380 3,199 3,104 3,450 3,873 13,626 68 % Selling, general and administrative 2,323 2,187 2,281 2,336 2,830 9,634 6 % Research and development 2,576 2,412 4,321 2,445 3,068 12,245 7 % Restructuring costs 53 297 82 107 174 661 -82 % Other expense, net 708 * Income from Continuing Operations Before Taxes 4,861 2,987 1,717 5,266 3,909 13,879 63 % Income Tax Provision 554 238 503 695 85 1,521 Net Income from Continuing Operations 4,307 2,749 1,214 4,571 3,824 12,358 57 % Less: Net Income Attributable to Noncontrolling Interests 4 1 4 4 13 Net Income from Continuing Operations..." |
|
| 03/25/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 02/03/2022 |
8-K
| Quarterly results |
| 12/10/2021 |
8-K
| Quarterly results |
| 10/28/2021 |
8-K
| Quarterly results|
Docs:
|
"Merck Announces Third-Quarter 2021 Financial Results",
"CONSOLIDATED STATEMENT OF INCOME - GAAP Table 1a 2021 2020 % Change 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD 4Q Full Year 3Q Sep YTD Sales $ 10,627 $ 11,402 $ 13,154 $ 35,183 $ 10,288 $ 9,353 $ 10,929 $ 30,570 $ 10,948 $ 41,518 20% 15% Costs, Expenses and Other Cost of sales 3,199 3,104 3,450 9,752 2,829 2,747 3,013 8,589 5,029 13,618 15% 14% Selling, general and administrative 2,187 2,281 2,336 6,804 2,191 2,085 2,060 6,336 2,619 8,955 13% 7% Research and development 2,412 4,321 2,445 9,177 2,175 2,085 3,349 7,609 5,788 13,397 -27% 21% Restructuring costs 297 82 107 487 70 82 113 265 310 575 -5% 84% Other expense, net 62 44% 58% Income from Continuing Operations Before Taxes 2,987 1,717 5,266 9,970 2,961 2,741 2,706 8,408 5,863 95% 19% Income Tax Provision 238 503 695 1,436 495 396 380 1,27..." |
|
| 08/20/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/29/2021 |
8-K
| Quarterly results|
Docs:
|
"Merck Announces Second-Quarter 2021 Financial Results",
"MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP Table 1a 2021 2020 % Change 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year 2Q June YTD Sales $ 10,627 $ 11,402 $ 22,029 $ 10,288 $ 9,353 $ 19,641 $ 10,929 $ 10,948 $ 41,518 22 % 12 % Costs, Expenses and Other Cost of sales 3,199 3,104 6,303 2,829 2,747 5,576 3,013 5,029 13,618 13 % 13 % Selling, general and administrative 2,187 2,281 4,468 2,191 2,085 4,276 2,060 2,619 8,955 9 % 4 % Research and development 2,412 4,321 6,732 2,175 2,085 4,260 3,349 5,788 13,397 * 58 % Restructuring costs 297 82 380 70 82 152 113 310 575 0 % * Other expense, net 62 -73 % 72 % Income from Continuing Operations Before Taxes 2,987 1,717 4,704 2,961 2,741 5,702 2,706 5,863 -37 % -18 % Income Tax Provision 238 503 741 495 396 891 380 69 1,340 Net Incom..." |
|
| 06/21/2021 |
8-K
| Quarterly results |
| 06/03/2021 |
8-K
| Quarterly results |
| 05/27/2021 |
8-K
| Quarterly results |
| 05/05/2021 |
8-K
| Quarterly results |
| 04/29/2021 |
8-K
| Quarterly results |
| 03/26/2021 |
8-K
| Quarterly results |
| 03/24/2021 |
8-K
| Quarterly results |
| 02/04/2021 |
8-K
| Quarterly results |
| 02/04/2021 |
8-K
| Quarterly results |
| 02/01/2021 |
8-K
| Quarterly results |
| 10/27/2020 |
8-K
| Quarterly results|
Docs:
|
"Merck Announces Third-Quarter 2020 Financial Results",
"MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP Table 1a 2020 2019 % Change 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD 4Q Full Year 3Q Sep YTD Sales $ 12,057 $ 10,872 $ 12,551 $ 35,479 $ 10,816 $ 11,760 $ 12,397 $ 34,972 $ 11,868 $ 46,840 1 % 1 % Costs, Expenses and Other Cost of sales 3,312 3,159 3,481 9,952 3,052 3,401 3,990 10,443 3,669 14,112 -13 % -5 % Selling, general and administrative 2,555 2,378 2,450 7,383 2,425 2,712 2,589 7,726 2,888 10,615 -5 % -4 % Research and development 2,209 2,123 3,390 7,721 1,931 2,189 3,204 7,324 2,548 9,872 6 % 5 % Restructuring costs 72 83 114 269 153 59 232 444 194 638 -51 % -39 % Other expense, net 71 188 140 35 362 139 * * Income Before Taxes 3,838 3,519 3,428 10,784 3,067 3,259 2,347 8,673 2,792 11,464 46 % 24 % Taxes on Income 619 509 483 1,6..." |
|
| 07/31/2020 |
8-K
| Quarterly results |
| 06/24/2020 |
8-K
| Quarterly results |
| 05/29/2020 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 04/28/2020 |
8-K
| Quarterly results|
Docs:
|
"Merck Announces First-Quarter 2020 Financial Results",
"MERCK & CO., INC. GAAP TO NON-GAAP RECONCILIATION FIRST QUARTER 2019 Table 2b GAAP Acquisition and Divestiture-Related Costs Restructuring Costs Certain Other Items Adjustment Subtotal Non-GAAP Cost of sales $ 3,052 413 34 447 $ 2,605 Selling, general and administrative 2,425 2,426 Research and development 1,931 1,962 Restructuring costs 153 153 153 - Other expense, net 188 167 167 21 Income Before Taxes 3,067 3,802 Income Tax Provision 205 627 Net Income 2,862 293 3,175 Less: Net Income Attributable to Noncontrolling Interests - Net Income Attributable to Merck & Co., Inc. 2,915 293 3,175 Earnings per Common Share Assuming Dilution $ 1.12 0.11 $ 1.22 Tax Rate 6.7 % 16.5 % Only the line items that are affected by non-GAAP adjustments are shown. Merck is providing certain non-GAA..." |
|
| 02/05/2020 |
8-K
| Quarterly results|
Docs:
|
"Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results",
"MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES FULL YEAR 2019 Table 3b Global U.S. International Full Year 2019 Full Year 2018 % Change Full Year 2019 Full Year 2018 % Change Full Year 2019 Full Year 2018 % Change TOTAL SALES $ 46,840 $ 42,294 11 $ 20,325 $ 18,212 12 $ 26,515 $ 24,083 10 PHARMACEUTICAL 41,751 37,689 11 18,759 16,608 13 22,992 21,081 9 Oncology Keytruda 11,084 7,171 55 6,305 4,150 52 4,779 3,021 58 Alliance Revenue - Lynparza 444 187 137 269 127 112 176 61 190 Alliance Revenue - Lenvima 404 149 171 239 95 152 165 54 * Emend 388 522 -26 183 312 -41 205 210 -2 Vaccines Gardasil / Gardasil 9 3,737 3,151 19 1,831 1,873 -2 1,905 1,279 49 ProQuad / M-M-R II / Varivax 2,275 1,798 27 1,683 1,430 18 592 368 61 Pneumovax 23 926 907 2 679 627 8 247 281 -12 RotaTeq 791 728 9 506 496 ...",
"Merck to Focus on Key Growth Pillars Through Spinoff of Women’ s Health, Trusted Legacy Brands and Biosimilars Products into New Company NewCo to be a Leading Women’ s Health Company; Represents Total Revenue of Approximately $6.5 Billion for Merck in 2020" |
|
| 01/31/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/29/2019 |
8-K
| Quarterly results |
| 07/30/2019 |
8-K
| Quarterly results|
Docs:
|
"Merck Announces Second-Quarter 2019 Financial Results",
"MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP Table 1a 2019 2018 % Change 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year 2Q June YTD Sales $ 10,816 $ 11,760 $ 22,575 $ 10,037 $ 10,465 $ 20,502 $ 10,794 $ 10,998 $ 42,294 12 % 10 % Costs, Expenses and Other Cost of sales 3,052 3,401 6,453 3,184 3,417 6,601 3,619 3,289 13,509 — -2 % Selling, general and administrative 2,425 2,712 5,138 2,508 2,508 5,016 2,443 2,643 10,102 8 % 2 % Research and development 1,931 2,189 4,119 3,196 2,274 5,470 2,068 2,214 9,752 -4 % -25 % Restructuring costs 153 59 212 95 228 323 171 138 632 -74 % -34 % Other expense, net 188 140 327 110 * * Income Before Taxes 3,067 3,259 6,326 1,345 2,086 3,432 2,665 2,604 8,701 56 % 84 % Taxes on Income 205 615 820 604 370 975 707 826 2,508 Net Income 2,862 2,644..." |
|
|
|
|